RESEARCH TRIANGLE PARK, N.C. — Joanna Horobin, president and chief executive officer of Syndax Pharmaceuticals, has joined the board of directors at RTP-based Nascent Pharmaceuticals.

Nascent is focused on development of ophthalmology and oncology drugs. It is currently seeking a business development and commercialization partner for its lead drug to treat dry eye.

Syndax is a startup focused on treatment of cancer. Before joining that company, Horobin was entrepreneur in residence at MPM Capital, an investor in life sciences. She has also worked for several biotechnology firms.

Nascent Pharmaceuticals: